Svensson Tobias, Lundström Kristina Lamberg, Höglund Martin, Cherif Honar
a Department of Medical Sciences , Section of Hematology, Uppsala University , Uppsala , Sweden.
b Department of Medical Sciences , Section of Pulmonology, Uppsala University Hospital , Uppsala , Sweden.
Ups J Med Sci. 2017 Mar;122(1):56-60. doi: 10.1080/03009734.2016.1237595. Epub 2016 Oct 14.
Patients treated for hematological malignancies have an increased risk of serious infections. Diagnosis and prompt initiation of therapy are essential. Bronchoalveolar lavage (BAL) is a well-established investigation for identifying the cause of pulmonary infiltrates in immunocompromised patients. The aim of the study was to determine the diagnostic yield of BAL in patients treated for hematological malignancies and how often it contributed to a modification of the anti-infectious therapy.
We reviewed records from 151 consecutive BAL procedures in 133 adult patients with hematological malignancies, treated at a tertiary hematology unit from 2004 to 2013. Extensive microbiological work-ups on BAL samples had been performed according to a standardized protocol.
A microbiological finding causing the infectious episode could be identified in 59 (39%) cases. In 44 (29%) of the cases, results from BAL had an impact on clinical management either by contributing to a specific diagnosis (25%) or by leading to cessation of ongoing microbiological therapy. The most common diagnoses were invasive pulmonary aspergillosis (IPA) and Pneumocystis jirovecii pneumonia (PJP). Diagnoses of IPA and PJP were based on results from BAL in 65% and 93% of cases, respectively. Several microbiological tests on BAL samples rendered no positive results. Complications were few and mainly mild.
BAL is still important for either verifying or excluding some of the most important respiratory tract pathogens in patients with hematological malignancies, particularly IPA and PJP. Standardized procedures for BAL sampling should be continually revised to exclude unnecessary microbiological tests.
接受血液系统恶性肿瘤治疗的患者发生严重感染的风险增加。诊断及迅速开始治疗至关重要。支气管肺泡灌洗(BAL)是确定免疫功能低下患者肺部浸润病因的一项成熟检查。本研究的目的是确定BAL在接受血液系统恶性肿瘤治疗患者中的诊断率,以及其促使抗感染治疗调整的频率。
我们回顾了2004年至2013年在一家三级血液科接受治疗的133例成年血液系统恶性肿瘤患者连续151次BAL操作的记录。已根据标准化方案对BAL样本进行了广泛的微生物学检查。
在59例(39%)病例中可确定导致感染发作的微生物学发现。在44例(29%)病例中,BAL结果对临床管理有影响,要么有助于明确诊断(25%),要么导致正在进行的微生物治疗停止。最常见的诊断是侵袭性肺曲霉病(IPA)和耶氏肺孢子菌肺炎(PJP)。IPA和PJP诊断分别在65%和93%的病例中基于BAL结果。对BAL样本进行的多项微生物学检测未得出阳性结果。并发症较少且主要为轻度。
BAL对于验证或排除血液系统恶性肿瘤患者中一些最重要的呼吸道病原体,特别是IPA和PJP,仍然很重要。应持续修订BAL采样的标准化程序,以排除不必要的微生物学检测。